Global Tumor Immune Cell Therapy Market Research Report 2026

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Immune Cell Therapy Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Chimeric Antigen Receptor T-cell Therapy
1.2.4 Tumor-Infiltrating Lymphocytes Therapy
1.2.5 Cancer Vaccines
1.2.6 Bispecific Antibodies
1.2.7 Cytokine Therapy
1.3 Market by Application
1.3.1 Global Tumor Immune Cell Therapy Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Hematological Tumors
1.3.3 Solid Tumors
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor Immune Cell Therapy Market Perspective (2021–2032)
2.2 Global Tumor Immune Cell Therapy Growth Trends by Region
2.2.1 Global Tumor Immune Cell Therapy Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Tumor Immune Cell Therapy Historic Market Size by Region (2021–2026)
2.2.3 Tumor Immune Cell Therapy Forecasted Market Size by Region (2027–2032)
2.3 Tumor Immune Cell Therapy Market Dynamics
2.3.1 Tumor Immune Cell Therapy Industry Trends
2.3.2 Tumor Immune Cell Therapy Market Drivers
2.3.3 Tumor Immune Cell Therapy Market Challenges
2.3.4 Tumor Immune Cell Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor Immune Cell Therapy Players by Revenue
3.1.1 Global Top Tumor Immune Cell Therapy Players by Revenue (2021–2026)
3.1.2 Global Tumor Immune Cell Therapy Revenue Market Share by Players (2021–2026)
3.2 Global Top Tumor Immune Cell Therapy Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Tumor Immune Cell Therapy Revenue
3.4 Global Tumor Immune Cell Therapy Market Concentration Ratio
3.4.1 Global Tumor Immune Cell Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Immune Cell Therapy Revenue in 2025
3.5 Global Key Players of Tumor Immune Cell Therapy Head Offices and Areas Served
3.6 Global Key Players of Tumor Immune Cell Therapy, Products and Applications
3.7 Global Key Players of Tumor Immune Cell Therapy, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Tumor Immune Cell Therapy Breakdown Data by Type
4.1 Global Tumor Immune Cell Therapy Historic Market Size by Type (2021–2026)
4.2 Global Tumor Immune Cell Therapy Forecasted Market Size by Type (2027–2032)
5 Tumor Immune Cell Therapy Breakdown Data by Application
5.1 Global Tumor Immune Cell Therapy Historic Market Size by Application (2021–2026)
5.2 Global Tumor Immune Cell Therapy Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Tumor Immune Cell Therapy Market Size (2021–2032)
6.2 North America Tumor Immune Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Tumor Immune Cell Therapy Market Size by Country (2021–2026)
6.4 North America Tumor Immune Cell Therapy Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor Immune Cell Therapy Market Size (2021–2032)
7.2 Europe Tumor Immune Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Tumor Immune Cell Therapy Market Size by Country (2021–2026)
7.4 Europe Tumor Immune Cell Therapy Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Tumor Immune Cell Therapy Market Size (2021–2032)
8.2 Asia-Pacific Tumor Immune Cell Therapy Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Tumor Immune Cell Therapy Market Size by Region (2021–2026)
8.4 Asia-Pacific Tumor Immune Cell Therapy Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Tumor Immune Cell Therapy Market Size (2021–2032)
9.2 Latin America Tumor Immune Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Tumor Immune Cell Therapy Market Size by Country (2021–2026)
9.4 Latin America Tumor Immune Cell Therapy Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor Immune Cell Therapy Market Size (2021–2032)
10.2 Middle East & Africa Tumor Immune Cell Therapy Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Tumor Immune Cell Therapy Market Size by Country (2021–2026)
10.4 Middle East & Africa Tumor Immune Cell Therapy Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 MEDINET Co
11.1.1 MEDINET Co Company Details
11.1.2 MEDINET Co Business Overview
11.1.3 MEDINET Co Tumor Immune Cell Therapy Introduction
11.1.4 MEDINET Co Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.1.5 MEDINET Co Recent Development
11.2 Erytech
11.2.1 Erytech Company Details
11.2.2 Erytech Business Overview
11.2.3 Erytech Tumor Immune Cell Therapy Introduction
11.2.4 Erytech Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.2.5 Erytech Recent Development
11.3 Seta Clinic Group
11.3.1 Seta Clinic Group Company Details
11.3.2 Seta Clinic Group Business Overview
11.3.3 Seta Clinic Group Tumor Immune Cell Therapy Introduction
11.3.4 Seta Clinic Group Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.3.5 Seta Clinic Group Recent Development
11.4 Takeda
11.4.1 Takeda Company Details
11.4.2 Takeda Business Overview
11.4.3 Takeda Tumor Immune Cell Therapy Introduction
11.4.4 Takeda Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.4.5 Takeda Recent Development
11.5 SBI Holdings
11.5.1 SBI Holdings Company Details
11.5.2 SBI Holdings Business Overview
11.5.3 SBI Holdings Tumor Immune Cell Therapy Introduction
11.5.4 SBI Holdings Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.5.5 SBI Holdings Recent Development
11.6 Oxford BioTherapeutics
11.6.1 Oxford BioTherapeutics Company Details
11.6.2 Oxford BioTherapeutics Business Overview
11.6.3 Oxford BioTherapeutics Tumor Immune Cell Therapy Introduction
11.6.4 Oxford BioTherapeutics Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.6.5 Oxford BioTherapeutics Recent Development
11.7 Fate Therapeutics
11.7.1 Fate Therapeutics Company Details
11.7.2 Fate Therapeutics Business Overview
11.7.3 Fate Therapeutics Tumor Immune Cell Therapy Introduction
11.7.4 Fate Therapeutics Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.7.5 Fate Therapeutics Recent Development
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Details
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Tumor Immune Cell Therapy Introduction
11.8.4 Gilead Sciences Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.8.5 Gilead Sciences Recent Development
11.9 Novartis
11.9.1 Novartis Company Details
11.9.2 Novartis Business Overview
11.9.3 Novartis Tumor Immune Cell Therapy Introduction
11.9.4 Novartis Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.9.5 Novartis Recent Development
11.10 Osiris
11.10.1 Osiris Company Details
11.10.2 Osiris Business Overview
11.10.3 Osiris Tumor Immune Cell Therapy Introduction
11.10.4 Osiris Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.10.5 Osiris Recent Development
11.11 Vericel Corporation
11.11.1 Vericel Corporation Company Details
11.11.2 Vericel Corporation Business Overview
11.11.3 Vericel Corporation Tumor Immune Cell Therapy Introduction
11.11.4 Vericel Corporation Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.11.5 Vericel Corporation Recent Development
11.12 Fujifilm Cellular Dynamics
11.12.1 Fujifilm Cellular Dynamics Company Details
11.12.2 Fujifilm Cellular Dynamics Business Overview
11.12.3 Fujifilm Cellular Dynamics Tumor Immune Cell Therapy Introduction
11.12.4 Fujifilm Cellular Dynamics Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.12.5 Fujifilm Cellular Dynamics Recent Development
11.13 JCR Pharmaceuticals
11.13.1 JCR Pharmaceuticals Company Details
11.13.2 JCR Pharmaceuticals Business Overview
11.13.3 JCR Pharmaceuticals Tumor Immune Cell Therapy Introduction
11.13.4 JCR Pharmaceuticals Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.13.5 JCR Pharmaceuticals Recent Development
11.14 Beike Biotechnology
11.14.1 Beike Biotechnology Company Details
11.14.2 Beike Biotechnology Business Overview
11.14.3 Beike Biotechnology Tumor Immune Cell Therapy Introduction
11.14.4 Beike Biotechnology Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.14.5 Beike Biotechnology Recent Development
11.15 Golden Meditech
11.15.1 Golden Meditech Company Details
11.15.2 Golden Meditech Business Overview
11.15.3 Golden Meditech Tumor Immune Cell Therapy Introduction
11.15.4 Golden Meditech Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.15.5 Golden Meditech Recent Development
11.16 Guanhao Biotech
11.16.1 Guanhao Biotech Company Details
11.16.2 Guanhao Biotech Business Overview
11.16.3 Guanhao Biotech Tumor Immune Cell Therapy Introduction
11.16.4 Guanhao Biotech Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.16.5 Guanhao Biotech Recent Development
11.17 Beroni Group
11.17.1 Beroni Group Company Details
11.17.2 Beroni Group Business Overview
11.17.3 Beroni Group Tumor Immune Cell Therapy Introduction
11.17.4 Beroni Group Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.17.5 Beroni Group Recent Development
11.18 Legend Biotech
11.18.1 Legend Biotech Company Details
11.18.2 Legend Biotech Business Overview
11.18.3 Legend Biotech Tumor Immune Cell Therapy Introduction
11.18.4 Legend Biotech Revenue in Tumor Immune Cell Therapy Business (2021–2026)
11.18.5 Legend Biotech Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Tumor Immune Cell Therapy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Immune Checkpoint Inhibitors
Table 3. Key Players of Chimeric Antigen Receptor T-cell Therapy
Table 4. Key Players of Tumor-Infiltrating Lymphocytes Therapy
Table 5. Key Players of Cancer Vaccines
Table 6. Key Players of Bispecific Antibodies
Table 7. Key Players of Cytokine Therapy
Table 8. Global Tumor Immune Cell Therapy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 9. Global Tumor Immune Cell Therapy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 10. Global Tumor Immune Cell Therapy Market Size by Region (US$ Million), 2021–2026
Table 11. Global Tumor Immune Cell Therapy Market Share by Region (2021–2026)
Table 12. Global Tumor Immune Cell Therapy Forecasted Market Size by Region (US$ Million), 2027–2032
Table 13. Global Tumor Immune Cell Therapy Market Share by Region (2027–2032)
Table 14. Tumor Immune Cell Therapy Market Trends
Table 15. Tumor Immune Cell Therapy Market Drivers
Table 16. Tumor Immune Cell Therapy Market Challenges
Table 17. Tumor Immune Cell Therapy Market Restraints
Table 18. Global Tumor Immune Cell Therapy Revenue by Players (US$ Million), 2021–2026
Table 19. Global Tumor Immune Cell Therapy Market Share by Players (2021–2026)
Table 20. Global Top Tumor Immune Cell Therapy Players by Tier (Tier 1, Tier 2, and Tier 3), based on Tumor Immune Cell Therapy Revenue, 2025
Table 21. Ranking of Global Top Tumor Immune Cell Therapy Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by Tumor Immune Cell Therapy Revenue (CR5 and HHI), 2021–2026
Table 23. Global Key Players of Tumor Immune Cell Therapy, Headquarters and Area Served
Table 24. Global Key Players of Tumor Immune Cell Therapy, Products and Applications
Table 25. Global Key Players of Tumor Immune Cell Therapy, Date of General Availability (GA)
Table 26. Mergers and Acquisitions, Expansion Plans
Table 27. Global Tumor Immune Cell Therapy Market Size by Type (US$ Million), 2021–2026
Table 28. Global Tumor Immune Cell Therapy Revenue Market Share by Type (2021–2026)
Table 29. Global Tumor Immune Cell Therapy Forecasted Market Size by Type (US$ Million), 2027–2032
Table 30. Global Tumor Immune Cell Therapy Revenue Market Share by Type (2027–2032)
Table 31. Global Tumor Immune Cell Therapy Market Size by Application (US$ Million), 2021–2026
Table 32. Global Tumor Immune Cell Therapy Revenue Market Share by Application (2021–2026)
Table 33. Global Tumor Immune Cell Therapy Forecasted Market Size by Application (US$ Million), 2027–2032
Table 34. Global Tumor Immune Cell Therapy Revenue Market Share by Application (2027–2032)
Table 35. North America Tumor Immune Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 36. North America Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2021–2026
Table 37. North America Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2027–2032
Table 38. Europe Tumor Immune Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 39. Europe Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2021–2026
Table 40. Europe Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2027–2032
Table 41. Asia-Pacific Tumor Immune Cell Therapy Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 42. Asia-Pacific Tumor Immune Cell Therapy Market Size by Region (US$ Million), 2021–2026
Table 43. Asia-Pacific Tumor Immune Cell Therapy Market Size by Region (US$ Million), 2027–2032
Table 44. Latin America Tumor Immune Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Latin America Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2021–2026
Table 46. Latin America Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2027–2032
Table 47. Middle East & Africa Tumor Immune Cell Therapy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 48. Middle East & Africa Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2021–2026
Table 49. Middle East & Africa Tumor Immune Cell Therapy Market Size by Country (US$ Million), 2027–2032
Table 50. MEDINET Co Company Details
Table 51. MEDINET Co Business Overview
Table 52. MEDINET Co Tumor Immune Cell Therapy Product
Table 53. MEDINET Co Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 54. MEDINET Co Recent Development
Table 55. Erytech Company Details
Table 56. Erytech Business Overview
Table 57. Erytech Tumor Immune Cell Therapy Product
Table 58. Erytech Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 59. Erytech Recent Development
Table 60. Seta Clinic Group Company Details
Table 61. Seta Clinic Group Business Overview
Table 62. Seta Clinic Group Tumor Immune Cell Therapy Product
Table 63. Seta Clinic Group Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 64. Seta Clinic Group Recent Development
Table 65. Takeda Company Details
Table 66. Takeda Business Overview
Table 67. Takeda Tumor Immune Cell Therapy Product
Table 68. Takeda Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 69. Takeda Recent Development
Table 70. SBI Holdings Company Details
Table 71. SBI Holdings Business Overview
Table 72. SBI Holdings Tumor Immune Cell Therapy Product
Table 73. SBI Holdings Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 74. SBI Holdings Recent Development
Table 75. Oxford BioTherapeutics Company Details
Table 76. Oxford BioTherapeutics Business Overview
Table 77. Oxford BioTherapeutics Tumor Immune Cell Therapy Product
Table 78. Oxford BioTherapeutics Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 79. Oxford BioTherapeutics Recent Development
Table 80. Fate Therapeutics Company Details
Table 81. Fate Therapeutics Business Overview
Table 82. Fate Therapeutics Tumor Immune Cell Therapy Product
Table 83. Fate Therapeutics Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 84. Fate Therapeutics Recent Development
Table 85. Gilead Sciences Company Details
Table 86. Gilead Sciences Business Overview
Table 87. Gilead Sciences Tumor Immune Cell Therapy Product
Table 88. Gilead Sciences Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 89. Gilead Sciences Recent Development
Table 90. Novartis Company Details
Table 91. Novartis Business Overview
Table 92. Novartis Tumor Immune Cell Therapy Product
Table 93. Novartis Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 94. Novartis Recent Development
Table 95. Osiris Company Details
Table 96. Osiris Business Overview
Table 97. Osiris Tumor Immune Cell Therapy Product
Table 98. Osiris Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 99. Osiris Recent Development
Table 100. Vericel Corporation Company Details
Table 101. Vericel Corporation Business Overview
Table 102. Vericel Corporation Tumor Immune Cell Therapy Product
Table 103. Vericel Corporation Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 104. Vericel Corporation Recent Development
Table 105. Fujifilm Cellular Dynamics Company Details
Table 106. Fujifilm Cellular Dynamics Business Overview
Table 107. Fujifilm Cellular Dynamics Tumor Immune Cell Therapy Product
Table 108. Fujifilm Cellular Dynamics Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 109. Fujifilm Cellular Dynamics Recent Development
Table 110. JCR Pharmaceuticals Company Details
Table 111. JCR Pharmaceuticals Business Overview
Table 112. JCR Pharmaceuticals Tumor Immune Cell Therapy Product
Table 113. JCR Pharmaceuticals Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 114. JCR Pharmaceuticals Recent Development
Table 115. Beike Biotechnology Company Details
Table 116. Beike Biotechnology Business Overview
Table 117. Beike Biotechnology Tumor Immune Cell Therapy Product
Table 118. Beike Biotechnology Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 119. Beike Biotechnology Recent Development
Table 120. Golden Meditech Company Details
Table 121. Golden Meditech Business Overview
Table 122. Golden Meditech Tumor Immune Cell Therapy Product
Table 123. Golden Meditech Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 124. Golden Meditech Recent Development
Table 125. Guanhao Biotech Company Details
Table 126. Guanhao Biotech Business Overview
Table 127. Guanhao Biotech Tumor Immune Cell Therapy Product
Table 128. Guanhao Biotech Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 129. Guanhao Biotech Recent Development
Table 130. Beroni Group Company Details
Table 131. Beroni Group Business Overview
Table 132. Beroni Group Tumor Immune Cell Therapy Product
Table 133. Beroni Group Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 134. Beroni Group Recent Development
Table 135. Legend Biotech Company Details
Table 136. Legend Biotech Business Overview
Table 137. Legend Biotech Tumor Immune Cell Therapy Product
Table 138. Legend Biotech Revenue in Tumor Immune Cell Therapy Business (US$ Million), 2021–2026
Table 139. Legend Biotech Recent Development
Table 140. Research Programs/Design for This Report
Table 141. Key Data Information from Secondary Sources
Table 142. Key Data Information from Primary Sources
Table 143. Authors List of This Report


List of Figures
Figure 1. Tumor Immune Cell Therapy Picture
Figure 2. Global Tumor Immune Cell Therapy Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Tumor Immune Cell Therapy Market Share by Type: 2025 vs 2032
Figure 4. Immune Checkpoint Inhibitors Features
Figure 5. Chimeric Antigen Receptor T-cell Therapy Features
Figure 6. Tumor-Infiltrating Lymphocytes Therapy Features
Figure 7. Cancer Vaccines Features
Figure 8. Bispecific Antibodies Features
Figure 9. Cytokine Therapy Features
Figure 10. Global Tumor Immune Cell Therapy Market Size by Application (US$ Million), 2021–2032
Figure 11. Global Tumor Immune Cell Therapy Market Share by Application: 2025 vs 2032
Figure 12. Hematological Tumors Case Studies
Figure 13. Solid Tumors Case Studies
Figure 14. Tumor Immune Cell Therapy Report Years Considered
Figure 15. Global Tumor Immune Cell Therapy Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 16. Global Tumor Immune Cell Therapy Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Tumor Immune Cell Therapy Market Share by Region: 2025 vs 2032
Figure 18. Global Tumor Immune Cell Therapy Market Share by Players in 2025
Figure 19. Global Tumor Immune Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 20. The Top 10 and 5 Players Market Share by Tumor Immune Cell Therapy Revenue in 2025
Figure 21. North America Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. North America Tumor Immune Cell Therapy Market Share by Country (2021–2032)
Figure 23. United States Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Canada Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Europe Tumor Immune Cell Therapy Market Share by Country (2021–2032)
Figure 27. Germany Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. France Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. U.K. Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Italy Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Russia Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Ireland Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Asia-Pacific Tumor Immune Cell Therapy Market Share by Region (2021–2032)
Figure 35. China Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Japan Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. South Korea Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Southeast Asia Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. India Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Australia & New Zealand Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Latin America Tumor Immune Cell Therapy Market Share by Country (2021–2032)
Figure 43. Mexico Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Brazil Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Middle East & Africa Tumor Immune Cell Therapy Market Share by Country (2021–2032)
Figure 47. Israel Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. Saudi Arabia Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. UAE Tumor Immune Cell Therapy Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. MEDINET Co Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 51. Erytech Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 52. Seta Clinic Group Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 53. Takeda Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 54. SBI Holdings Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 55. Oxford BioTherapeutics Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 56. Fate Therapeutics Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 57. Gilead Sciences Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 58. Novartis Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 59. Osiris Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 60. Vericel Corporation Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 61. Fujifilm Cellular Dynamics Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 62. JCR Pharmaceuticals Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 63. Beike Biotechnology Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 64. Golden Meditech Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 65. Guanhao Biotech Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 66. Beroni Group Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 67. Legend Biotech Revenue Growth Rate in Tumor Immune Cell Therapy Business (2021–2026)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit